DOAJ
Open Access
2021
Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity
Dipsikha Biswas
Logan Slade
Luke Duffley
Neil Mueller
Khoi Thien Dao
+5 lainnya
Abstrak
Proposed mechanism. A Doxorubicin (DOX) targets the BCAA catabolic pathway in TNBCs, by downregulating BCKDK and augmenting clearance of intracellular BCKAs. B Genetic or pharmacological (high BT2 concentration) inhibition of BCKDK results in increased cell death, decreased intracellular BCKAs, dysregulated mitochondrial function, ATP insufficiency, SESN2 activation, and inhibition of mTORC1 signaling and protein synthesis. C BCKDK inhibition (siRNA mediated or low-BT2 concentration) exacerbates DOX-induced cytotoxicity and caspase activity.
Topik & Kata Kunci
Penulis (10)
D
Dipsikha Biswas
L
Logan Slade
L
Luke Duffley
N
Neil Mueller
K
Khoi Thien Dao
A
Angella Mercer
S
Shanmugasundaram Pakkiriswami
Y
Yassine El Hiani
P
Petra C. Kienesberger
T
Thomas Pulinilkunnil
Format Sitasi
Biswas, D., Slade, L., Duffley, L., Mueller, N., Dao, K.T., Mercer, A. et al. (2021). Inhibiting BCKDK in triple negative breast cancer suppresses protein translation, impairs mitochondrial function, and potentiates doxorubicin cytotoxicity. https://doi.org/10.1038/s41420-021-00602-0
Akses Cepat
Informasi Jurnal
- Tahun Terbit
- 2021
- Sumber Database
- DOAJ
- DOI
- 10.1038/s41420-021-00602-0
- Akses
- Open Access ✓